• Markets
    • icon
  • Companies
TLX · ASX

Telix Pharmaceuticals Ltd. (ASX:TLX)

AU$9.62

 0.22 (2.34%)
ASX:Live
28/11/2023 04:10:31 PM
HALO Small HALO Ords HALO Capital Efficiency HALO Balance Sheet HALO 200 +5
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

TLX Overview

TLX Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About TLX

Website

Telix Pharmaceuticals Ltd.

Telephone

N/A

Address

North Melbourne Suite 401 55 Flemington Road Melbourne, Victoria (VIC) 3051

Description

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TX250, TX591, and TX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

TLX Price Chart

Key Stats

Market Cap

AU$3.03B

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 5.82 - 12.79

Trade Value (12mth)

AU$2,570,042.00

1 week

5.25%

1 month

10.7%

YTD

37.23%

1 year

31.96%

All time high

12.79

Key Fundamentals

EPS 3 yr Growth

180.600%

EBITDA Margin

-42.40%

Operating Cashflow

-$64m

Free Cash Flow Return

-136.30%

ROIC

-221.70%

Interest Coverage

-167.00

Quick Ratio

1.90

Other Data

Shares on Issue (Fully Dilluted)

318m

HALO Sector

Healthcare

Next Company Report Date

26-Feb-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

1.66

TLX Announcements

Latest Announcements

Date Announcements

31 May 18

CEO presentation to Wilsons Rapid Insights Conference

×

CEO presentation to Wilsons Rapid Insights Conference

31 March 22

Change of Composition of the Telix Board of Directors

×

Change of Composition of the Telix Board of Directors

31 March 22

Appendix 3X - Initial Directors Interest Notice

×

Appendix 3X - Initial Directors Interest Notice

31 January 22

App 3Y Change of Directors Interest Notice - C Behrenbruch

×

App 3Y Change of Directors Interest Notice - C Behrenbruch

31 January 22

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

31 January 22

Notice of change of interests of substantial holder

×

Notice of change of interests of substantial holder

31 January 22

Cleansing Notice under S708A(5)(e) Corporations Act 2001

×

Cleansing Notice under S708A(5)(e) Corporations Act 2001

31 January 22

Notice of change of interests of substantial holder

×

Notice of change of interests of substantial holder

31 January 22

App 3Y Change of Directors Interest Notice - A Kluge

×

App 3Y Change of Directors Interest Notice - A Kluge

31 January 22

Despatch of SPP Booklet to Eligible Shareholders

×

Despatch of SPP Booklet to Eligible Shareholders

30 May 23

Securities Dealing Policy - updated

×

Securities Dealing Policy - updated

30 May 22

Illuccix Reimbursement Milestone and Launch Updates

×

Illuccix Reimbursement Milestone and Launch Updates

30 December 22

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

30 December 22

Cleansing Notice

×

Cleansing Notice

29 March 23

Non-Executive Director Leave of Absence

×

Non-Executive Director Leave of Absence

29 March 22

Telix and Xiel Sign U.K. and Ireland Distribution Agreement

×

Telix and Xiel Sign U.K. and Ireland Distribution Agreement

29 March 22

FDA Orphan Drug Designation for Bone Marrow Conditioning

×

FDA Orphan Drug Designation for Bone Marrow Conditioning

29 August 22

Notification of cessation of securities - TLX

×

Notification of cessation of securities - TLX

29 August 22

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

29 August 22

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

28 September 22

Telix Withdraws Marketing Application for Illuccix in Europe

×

Telix Withdraws Marketing Application for Illuccix in Europe

28 September 22

Chinese NMPA Approves TLX250 Phase III registration study

×

Chinese NMPA Approves TLX250 Phase III registration study

28 November 22

Release of shares from voluntary escrow

×

Release of shares from voluntary escrow

28 November 22

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

28 November 22

Cleansing Notice

×

Cleansing Notice

28 June 23

Application for quotation of securities - TLX

×

Application for quotation of securities - TLX

28 June 23

Cleansing Notice

×

Cleansing Notice

TLX Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.17 -0.29 -0.34 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.17 -0.29 -0.34 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.1 -63.5 -17.4 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.11 -0.20 -0.20 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.01 -0.21 -0.23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.4 -86.8 -0.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.2 -2.8 -3.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.28 0.01 0.25 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.07 -0.19 0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -36.3 -365.8 135.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 257 282 311 Lock Lock Lock
Basic m Lock Lock Lock Lock 257 282 311 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Income Statement
Sales $m Lock Lock Lock Lock 5 8 160 Lock Lock Lock
     Growth % Lock Lock Lock Lock 49.6 45.7 2,007.6 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 32 51 103 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -17 -30 29 Lock Lock Lock
     Growth % Lock Lock Lock Lock -42.1 -76.4 198.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -323.7 -391.9 18.3 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 424 492 82 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -44 -76 -68 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.2 -71.4 10.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -851.2 -1,001.5 -42.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 5 5 5 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -49 -81 -73 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.3 -65.0 9.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -944.8 -1,069.6 -45.7 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -60 -99 -99 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -15 -19 5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -45 -81 -104 Lock Lock Lock
     Growth % Lock Lock Lock Lock -61.1 -79.4 -29.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -861.1 -1,059.9 -65.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 2 -59 -64 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 14 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -3 -17 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 34 3 175 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 2 -61 -71 Lock Lock Lock
     Growth % Lock Lock Lock Lock 107.2 -3,643.6 -17.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.3 -8.0 -0.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 78 22 116 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 164 110 261 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 2 10 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -76 -19 -106 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 84 106 178 Lock Lock Lock
Equity $m Lock Lock Lock Lock 79 2 80 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 80 4 90 Lock Lock Lock
     Growth % Lock Lock Lock Lock 12.2 -94.9 2,109.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -27.3 -73.3 -39.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -56.8 -3,730.8 -130.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -64.2 -189.1 -153.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -59.0 -190.5 -221.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 2.6 -140.4 -136.3 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Leverage
Interest Cover X Lock Lock Lock Lock -37.8 -402.5 -167.0 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.7 0.3 1.6 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -95.9 -903.5 -132.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 4.7 1.3 2.0 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 4.7 1.2 1.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 83.2 46.4 67.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 9.8 -156.2 -74.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.4 0.4 4.8 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 37.6 18.3 21.9 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.8 1.8 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 111.4 156.5 10.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.6 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.6 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,155.8 -1,303.8 -61.6 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -36.6 -90.2 -37.8 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -27.3 -73.3 -39.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 2.1 50.9 3.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -56.8 -3,730.8 -130.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -56.8 -3,730.8 -130.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 9.7 20.0 16.7 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 952.2 841.8 76.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 961.9 861.7 92.8 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 105.1 80.4 38.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 856.9 781.4 54.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

1.66%

Value ($M)

50

Prior Change

N/A

7 Day Change

-0.10%

1 Month Change

0.10%

3 Month Change

0.60%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

TLX Shortsell

Frequently Asked Questions

The current share price of Telix Pharmaceuticals Ltd. (TLX:ASX) is AU$9.62.
The 52-week high share price for Telix Pharmaceuticals Ltd. (TLX:ASX) is AU$12.79.
The 52-week low share price for Telix Pharmaceuticals Ltd. (TLX:ASX)? is AU$5.82.
Telix Pharmaceuticals Ltd. (TLX:ASX) does not pay a dividend.
Telix Pharmaceuticals Ltd. (TLX:ASX) does not pay a dividend.
Telix Pharmaceuticals Ltd. (TLX:ASX) has a franking level of 0%.
Telix Pharmaceuticals Ltd. (TLX:ASX) is classified in the Healthcare.
The current P/E ratio for Telix Pharmaceuticals Ltd. (TLX:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.